
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Invitrocue Limited is a biotechnology business based in Australia. Invitrocue shares (IVQ) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Invitrocue has a market cap (total outstanding shares value) of $34.7 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.06 - $0.06 |
---|---|
50-day moving average | $0.06 |
200-day moving average | $0.06 |
Target price | $0.47 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.007 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Gross profit TTM | $252,858 |
---|---|
Return on assets TTM | -167.33% |
Return on equity TTM | -1214.48% |
Profit margin | 0% |
Book value | 0.003 |
Market capitalisation | $34.7 million |
TTM: trailing 12 months
We're not expecting Invitrocue to pay a dividend over the next 12 months.
Invitrocue 's shares were split on a 1:52 basis on 19 May 2015. So if you had owned 52 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Invitrocue shares – just the quantity. However, indirectly, the new 5100% higher share price could have impacted the market appetite for Invitrocue shares which in turn could have impacted Invitrocue 's share price.
Over the last 12 months, Invitrocue 's shares have ranged in value from as little as $0.06 up to $0.06. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Invitrocue 's is 0.3473. This would suggest that Invitrocue 's shares are less volatile than average (for this exchange).
Invitrocue Limited engages in the research and experimental development on biotechnology, life, and medical science primarily in Singapore, Australia, China, Hong Kong, and Germany. The company develops Onco Patient-Derived Organoid (PDO) test, a personalized cancer treatment for cancer patients; and 3D CelluSponge series, a 3D in-vitro platform technology for various applications, including 3D cell culture, hepatocyte culture, in-vitro drug metabolism and pharmacokinetics assays and toxicology, stem cell differentiation, PDO, and pathogen infection and detection. It also provides respiratory disease, and customized assays and disease modelling services. Invitrocue Limited was founded in 2012 and is headquartered in Singapore.
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
We explain everything you need to make your own retro arcade machine, built around the super-flexible Raspberry Pi.
Beat the banks, find the best exchange rates and avoid fees when you send money abroad from Australia.
All the key info you need to know to sell shares you inherited or received as a gift.
Steps to owning and managing Roblox shares.
Steps to owning and managing Zebit shares.
Steps to owning and managing CleanSpace shares.
Steps to owning and managing Benz Mining shares.